Kestra Medical Technologies, Ltd.
Cash Flow Statement
| Line Item | FY2026 | FY2025 | FY2024 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $-131.6M | $-113.8M | $-94.1M |
| Depreciation & Amortization | $8.7M | $8.0M | $11.6M |
| Depreciation | $8.7M | $8.0M | $11.6M |
| Amortization | — | — | — |
| Stock-Based Compensation | $33.6M | $24.3M | $1.5M |
| Net Cash from Operating Activities | $-81.7M | $-77.6M | $-72.2M |
| Investing Activities | |||
| Capital Expenditures | $34.9M | $22.9M | $12.2M |
| Business Acquisitions | — | — | — |
| Net Cash from Investing Activities | $-203.3M | $-23.3M | $-12.2M |
| Financing Activities | |||
| Dividends Paid | — | — | — |
| Stock Repurchases | — | — | — |
| Net Cash from Financing Activities | $147.1M | $330.3M | $77.7M |
| Net Change in Cash | $-137.9M | $229.3M | $-6.7M |
| Free Cash Flow | $-116.6M | $-100.5M | $-84.5M |